

BIOGRAPHICAL SKETCH

NAME Ana Paula Velez, MD		POSITION TITLE Assistant Professor, University of South Florida, Department of Internal Medicine, Division of Infectious Disease and International Medicine	
eRA COMMONS USER NAME			
EDUCATION/TRAINING			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
Instituto Ciencias de la Salud, Medellin, Colombia	MD	1996	
Hospital General de Medellin, Medellin, Colombia	Intern	1995-1996	General Medicine
San Juan City Hospital, San Juan, PR	Intern	2001-2002	Internal Medicine
Orlando Regional Medical Center, Orlando, FL	Residency	2002-2004	Internal Medicine
University of South Florida, Tampa, FL	Fellow	2005-2006	Infectious Diseases and International Medicine

A. Positions and Honors.**Positions and Employment**

2009-present	Vice Chief of Infectious Disease, H. Lee Moffitt Cancer Center, Tampa, FL
2007-present	Faculty, Florida/Caribbean AIDS Education and Training Center, Tampa, FL
2007-present	Assistant Professor of Medicine, Division of Infectious Diseases and International Medicine, University of South Florida, Tampa, FL
2007-2008	HIV Lead Clinician, James A. Haley Veteran's Hospital, Tampa, FL
2007-2008	Senior Physician, Polk County Health Department, Bartow, FL
2004-2006	Chief Fellow, Division of Infectious Disease and International Medicine, University of South Florida, Tampa, FL
1999-2000	Physician, Social Services, Hospital San Cristobal, Medellin, Colombia

Other Experience and Professional Memberships

2007-2019	Diplomate, American Board of Internal Medicine, Infectious Diseases
2005-2015	Diplomate, American Board of Internal Medicine
2005-present	Member, American Medical Association
2005-present	Member, Infectious Diseases Society of America
2002-present	Member, American College of Physicians
2005	Member, American Society of Microbiology

Awards and Honors

2008	Tackling the Topic of Infectious Diseases in Espanol, University of South Florida, Tampa, FL
2007	Cambridge Who's Who. Honored Member.
2006	IDSFA Fellow's Travel Grant in recognition of excellence in the abstract "Disseminated Fusarium Following Palm Tree Induced Injury in a Patient after Allogenic Stem Cell Transplantation despite Voriconazole Prophylaxis"
2003	Resident of 4 th Quarter, Orlando Regional Center
2002	First place in Original Research Presentation for Clinical Outcomes of Activated Drotrecogin Alpha. Orlando Regional Medical Center, Orlando, FL

B. Peer-reviewed publications

1. **Velez AP**, Baluch A, Greene J. Onychomycosis in neutropenic patients, Clinical of Infectious Diseases – pending submission.

2. **Velez AP**, Greene J. Disseminated Fusarium Following Palm Tree Induced Injury in a Patient Following Allogeneic Stem Cell Transplantation Despite Voriconazole Prophylaxis, *Infect in Med*. 2008 25:528-530.
3. **Velez A**, Menezes L, Crespo A. Kawasaki-Like Syndrome During Immune Reconstitution in a Patient with AIDS. *Illustrated Cases HIV/AIDS Journal*. September 2007; 13-15.
4. **Velez A**, Menezes L, Crespo A. Kawasaki-Like Syndrome During Immune Reconstitution in a Patient with AIDS. *AIDS Reader*. 2006;16:464-466.
5. Oehler R, **Velez A**, Mizrachi M, et al. Bite-related and septic syndromes caused by cats and dogs. The Lancet of Infectious Diseases. *Lancet Infect Dis*. 2009 Jul; 9(7):439-47.
6. Oehler R, **Velez A**, Mizrachi M, et al. "'Down Boy" Infectious Diseases Spread by Cats and Dogs". *Infectious Diseases in Clinical Practice*. 2009 Sept: 17(5): 298-305.
7. Somboonwit C, Kurtyka D, **Paula Velez A**. Abacavir and lamivudine combination. *Expert Opinion on Drug Metabolism and Toxicology*. 2009: 5(12): 1599-1606.
8. Kharfan-Dabaja M, **Velez A**, Richards K, et al. Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. *Int J hematol*. 2010; 91:124-127.

C. Research Support

Tibotec – TMC125-C217

2007

A randomized, controlled, partially blinded Phase IIb dose-finding trial of TMC125, in HIV-1 infected subjects with documented genotypic evidence of resistance to currently available NNRTIs and with at least three primary PI mutations.

Tibotec (TMC125-C206)

2006

USF # 104265; DOH # H05074. A Phase III Randomized, Double-Blinded, Placebo-Controlled Rrial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Including TMC114/RTV and an Investigator-Selected OBR in HIV-1 Infected Subjects with Limit to No Treatment Options.

Gilead (GS-US-183-0105)

2006

USF # 104491c; DOH # H06018. A Pase 2, Randomized Study of the Treatment of Antiretroviral Treatment-Experienced, HIV-1 Infected Subjects Comparing Ritonavir-Boosted GS-9137 (GS-9137/r) Versus a Comparator Ritonavir-Boosted Protease Inhibitor (CPI/r) in Combination with a Background Antiretroviral Therapy.

Agouron/Pfizer (A4001027)

2006

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination with Optimized Backgroup Therapy Versus Optimized Background Therapy Along for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subject

Tibotec (TMC125-C223)

2006

A Rendomized, Controlled, Parially Blinded Phase IIb Dose-Finding Trial of TMC125, in HIV-1 Infected Subjects with Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations.

Achillion (ACH443-015)

2006

USF # 104757; DOH # H06037. A Phase II, Randomized, Blinded, 12-Week Comparison of Elvucitabine in Combination with Efavirenz and Tenofovir Versus Lamivudine in Combination with Efavirenz and Tenofovir in HIV-1 Infected, Treatment-Naïve Subjects with a 12-Week Extension Treatment Period.

SMART

2006

USF # 101250c; DOH # H1207. A Large, Simple Trial Comparing Two Strategies for Management of Anti-Retroviral Therapy. SMART CPCRA

- Tibotec (TMC114-C211) 2006
USF # 104244b; DOH # H06003. A Randomized, Controlled, Open-Label Trial to Compare the Efficacy, Safety and Tolerability of TMC114/Ritonavir Versus Lopinavir/Ritonavir in Treatment-Naive HIV-1 Infected Subjects. This trial will be referred to as ARTEMIS.
- Tibotec (TMC278-C204) 2006
USF # 103524; DOH #1455. A Phase I/II, Randomized, Partially Blinded, Dose-Finding Trial of TM278 in Antiretroviral Naive HIV-1 Infected Subjects.
- Tibotec (TMC125-C229) 2006
USF # 103726; DOH # 1475. An Open-Label Trial with TMC125 in HIV-1 Infected Subjects Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks.
- GlaxoSmithKline (EPZ104057) 2006
USF # 104025; DOH # H05081. A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of Epzicom Versus Truvada Administered in Combination with Kaletra in Antiretroviral-naive HIV-1 Infected Subjects. HEAT.
- GlaxoSmithKline (COL100758) 2006
USF # 103473; DOH # 1431. A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908/Ritonavir Given with Abacavir/Lamivudine Fixed Dose Combination.
- Merck (V520-014) 2006
USF # 100036d; DOH # 1098. A Probe Study to Evaluate the Safety, Tolerability, and Immunogenicity of the MRK Adenovirus Serotype 5 Vector (MRKAd5) Human Immunodeficiency Virus Type I (HIV-1) gag Vaccine in HIV-1 Infected Individuals.
- Tibotec (TMC114-C214) 2006
USF # 103681; DOH #1469. A Randomized, Controlled, Open-Trial to Compare the Efficacy, Safety and Tolerability of TMC114/RTV versus LPV/RTV in Treatment-Experiences HIV-1 Infected Subjects.